title: [Impact of obesity on PSA in prostate cancer screening].
abstract: OBJECTIVE
  Obesity is associated with changes of serum levels of androgens and oestrogens which could modulate prostate metabolism. The objective of this study was to investigate a possible correlation between the PSA level and the degree of obesity in a candidate population for prostate cancer screening in order to determine whether the PSA level needs to be adapted before performing biopsy.
  
  
  METHODS
  During a screening campaign in a French district, serum PSA results and body mass index (BMI) were available for 541 men. These men were divided into 4 groups of corpulence: Normal (BMI < 25), Overweight (25 < or = BMI < 30), Stage I obesity (30 < or = BMI < 35), Stage II + III obesity (BMI > or = 35). The PSA levels of these various groups were compared, and a correlation between BMI and PSA was investigated.
  
  
  RESULTS
  The mean PSA in each group was inversely proportional to BMI, with mean PSA levels of 3.7, 2.9, 2.6 and 1.5 for Normal, Overweight, Obesity I and Obesity II + III groups, respectively. A significant difference was observed between these groups (p = 0.03) and an inverse correlation was also observed between BMI and PSA (r = 0.1, p = 0.01).
  
  
  CONCLUSIONS
  In a population submitted to prostate cancer screening, PSA is lower as BMI increases. An adaptation of the PSA screening cutoff value according to BMI should be investigated.
authors.affiliation: Centre de Recherche pour les Pathologies Prostatiques (CeRePP), EA3104 Université Paris 7, UFR Biomédicales des Saint-Pères, Paris, France. stephane.larre@hmn.aphp.fr
authors.forename: Stéphane
authors.initials: S
authors.lastname: Larré
authors.forename: Abdel Rahmène
authors.initials: AR
authors.lastname: Azzouzi
authors.forename: Géraldine
authors.initials: G
authors.lastname: Cancel-Tassin
authors.forename: Luc
authors.initials: L
authors.lastname: Cormier
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Villette
authors.forename: Philippe
authors.initials: P
authors.lastname: Hoffmann
authors.forename: Isabelle
authors.initials: I
authors.lastname: Drelon
authors.forename: Françoise
authors.initials: F
authors.lastname: Baschet
authors.forename: Philippe
authors.initials: P
authors.lastname: Mangin
authors.forename: Olivier
authors.initials: O
authors.lastname: Cussenot
mesh_terms: D006801:Humans; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D009765:Obesity / Q000097:blood* / Q000150:complications; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000150:complications / Q000175:diagnosis*
chemical_list: D017430:Prostate-Specific Antigen